Continuation or reintroduction of bevacizumab beyond progression to first-line therapy in metastatic colorectal cancer: final results of the randomized BEBYP trial.
about
Anti-angiogenic agents in metastatic colorectal cancerRelationship between hypoxia and response to antiangiogenic therapy in metastatic colorectal cancerTreatment with Antiangiogenic Drugs in Multiple Lines in Patients with Metastatic Colorectal Cancer: Meta-Analysis of Randomized TrialsSecond-line systemic therapy for metastatic colorectal cancer.TRIBE-2: a phase III, randomized, open-label, strategy trial in unresectable metastatic colorectal cancer patients by the GONO group.Bevacizumab plus chemotherapy as third- or later-line therapy in patients with heavily treated metastatic colorectal cancer.SEOM clinical guidelines for diagnosis and treatment of metastatic colorectal cancer 2015.Angiogenesis genotyping and clinical outcome during regorafenib treatment in metastatic colorectal cancer patients.Targeted vaccination against the bevacizumab binding site on VEGF using 3D-structured peptides elicits efficient antitumor activity.Antiangiogenic therapy for refractory colorectal cancer: current options and future strategies.Hepatic artery infusion with raltitrexed or 5-fluorouracil for colorectal cancer liver metastasis.Prognostic factors for transarterial chemoembolization combined with sustained oxaliplatin-based hepatic arterial infusion chemotherapy of colorectal cancer liver metastasis.Low-value practices in oncology contributing to financial toxicity.Nintedanib in combination with docetaxel for second-line treatment of advanced non-small-cell lung cancer.Current and advancing treatments for metastatic colorectal cancer.Bevacizumab in Colorectal Cancer: Current Role in Treatment and the Potential of Biosimilars.Ramucirumab for the treatment of gastric cancers, colorectal adenocarcinomas, and other gastrointestinal malignancies.Surrogate Endpoints in Second-Line Trials of Targeted Agents in Metastatic Colorectal Cancer: A Literature-Based Systematic Review and Meta-Analysis.The potential role of nintedanib in treating colorectal cancer.Efficacy and safety of nab-paclitaxel in patients with previously treated metastatic colorectal cancer: a phase II COLO-001 trial.Recent developments in the treatment of metastatic colorectal cancer.Impact of second-line cetuximab-containing therapy in patients with KRAS wild-type metastatic colorectal cancer: results from the ITACa randomized clinical trial.Efficacy and safety for Apatinib treatment in advanced gastric cancer: a real world study.KRAS mutation and primary tumor location do not affect efficacy of bevacizumab-containing chemotherapy in stagae IV colorectal cancer patients.Final results of the TANIA randomised phase III trial of bevacizumab after progression on first-line bevacizumab therapy for HER2-negative locally recurrent/metastatic breast cancer.An Update on Randomized Clinical Trials in Metastatic Colorectal Carcinoma.Successful treatment of metastatic colorectal cancer with apatinib: report of two cases and literature review.Serum LDH predicts benefit from bevacizumab beyond progression in metastatic colorectal cancer.Aflibercept Plus FOLFIRI vs. Placebo Plus FOLFIRI in Second-Line Metastatic Colorectal Cancer: a Post Hoc Analysis of Survival from the Phase III VELOUR Study Subsequent to Exclusion of Patients who had Recurrence During or Within 6 Months of CompleManagement of metastatic colorectal cancer patients: guidelines of the Italian Medical Oncology Association (AIOM).Risk of bleeding associated with antiangiogenic monoclonal antibodies bevacizumab and ramucirumab: a meta-analysis of 85 randomized controlled trials
P2860
Q26801911-A53FF02D-3682-47DD-9977-DF12D3703D40Q28068654-915213CA-B16E-4B4C-9EA7-207F706591BFQ28071933-68BD3ED2-07DD-4D85-ACC8-2638170B82FDQ30238760-DFFF0AE0-8D48-4CD9-89DB-ACE1351169E5Q30855372-445A7D7E-468A-4051-8998-2BAD852BCD30Q33425820-DE443355-C7F9-419E-92B2-44C97067DDC1Q36400301-88F13E9D-8450-4163-8425-677BB2A4F136Q36841039-CF2E5FA1-35A2-43F9-98CA-EA74D23077ABQ37398065-520B3091-DE6C-482F-B7CA-840A71EE45B3Q37632167-B79E897C-F93C-4119-B22C-DA190F635152Q37672223-0EBF2724-E4BC-45F3-B74E-F34FDACA84F4Q37697312-A09051B5-848F-410A-9B94-767FE92AF41FQ37720714-AEDC9B26-92F0-493A-B8B3-8F3354A40D50Q38552883-8DECC7AC-36AA-4015-BC7E-4125B6A78AFCQ38628257-18F11300-0E2C-4984-BF9A-4E9F0F2DB9B4Q38643555-34D57110-446F-4C77-8531-DA8D6D0F0DB7Q38826507-31BBEAF7-2EF8-4063-8EF2-5A1BD9D85284Q39011428-2295D68C-8F6B-424E-95DE-9FD17EBBB7C7Q39398037-D7F074D7-7315-46AB-9456-2E43C0E65C37Q40466159-368EACB0-8C84-4180-81BD-FF63EC0F88C4Q41105389-B1A350BA-CCF5-4DA1-AF6A-EC0D4A3C0B1BQ41621356-73EEE137-2355-4897-8FD1-FC07017AC02CQ42378852-D9E7DEE9-208D-4526-A1DE-A6E2C735530AQ47165594-B7DA9565-13A4-43B8-B29B-188F3B4FC74AQ47632061-A592B68A-1D96-4536-842C-46F1D5D4BE86Q50041173-DF1091D3-41BB-4F07-8FEB-803507D7A767Q50350183-A8E31D02-5629-4C46-A329-82B0940F99B0Q51195465-3792FBDD-3034-4721-8B6B-07600D08C742Q53779084-B3FF65B3-31BD-4E75-811C-E6BE047C6992Q55032398-14406D09-C258-45A8-AB16-1D889579EFEAQ58729601-1D1503DF-4428-46F3-BD31-503D41E5D50E
P2860
Continuation or reintroduction of bevacizumab beyond progression to first-line therapy in metastatic colorectal cancer: final results of the randomized BEBYP trial.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Continuation or reintroduction ...... of the randomized BEBYP trial.
@en
type
label
Continuation or reintroduction ...... of the randomized BEBYP trial.
@en
prefLabel
Continuation or reintroduction ...... of the randomized BEBYP trial.
@en
P2093
P2860
P50
P356
P1433
P1476
Continuation or reintroduction ...... of the randomized BEBYP trial
@en
P2093
BEBYP Study Investigators
C Cremolini
C Granetto
G Allegrini
P2860
P304
P356
10.1093/ANNONC/MDV012
P577
2015-01-18T00:00:00Z